## <TEMPLATE>

## **LETTER OF ACCESS FOR CEP**

## < Certificate of Suitability (CEP)> <Letter of Access (LOA)>

<active :="" ingredient="" name="" pharmaceutical=""></active>
<cep :="" address="" and="" holders="" name=""></cep>
<active :="" ingredient="" manufacturing="" pharmaceutical="" site(s)=""></active>
<apimf :="" number="" version=""></apimf>
<open :="" part=""></open>
<closed :="" part=""></closed>
< {CEP Holders Name}, hereby authorizes the relevant NAFDAC staff members and external experts to refer to and review the above-mentioned CEP <cep number(s)=""> in support application(s) submitted by {Applicants Name/Address} for the following product&gt;</cep>
< (FPP product generic name), (strength) and (dosage form) (NAFDAC- Assigned reference number if known)>
<the aforementioned="" and="" any="" api="" api.="" apimf="" approval="" as="" batch-to-batch="" be="" before="" by="" cep="" change="" changes="" closed="" committed="" consistency="" control="" destined="" distributed="" ensuring="" except="" granted="" guidelines="" holder="" in="" informing="" is="" made="" manufacture="" manufacture,="" manufacturing="" medicine="" medicines,="" nafdac="" nafdac.<="" name}="" nigeria="" not="" of="" open="" or="" p="" parts="" permitted="" procedure="" quality="" relating="" significant="" site="" specifications="" such="" the="" to="" used="" will="" written="" {applicants=""></the>
It is understood that the consequences of failure to obtain approval for changes where approval is necessary may include de-registration and recall of batches of medicines.>
<name &="" of="" officer="" responsible="" signature=""></name>

<Designation>